共查询到20条相似文献,搜索用时 15 毫秒
1.
2.
3.
Allen Jeremias MD MSc Sujethra Vasu MD Luis Gruberg MD Adnan Kastrati MD Gregg W. Stone MD David L. Brown MD 《Catheterization and cardiovascular interventions》2010,75(6):895-902
Objectives: To combine data from all randomized trials of abciximab versus placebo or open‐label control in patients with STEMI treated with primary stenting to assess the short‐term and long‐term mortality, reinfarction, and bleeding complications. Background: Clinical trials of adjunctive abciximab therapy in patients with ST‐segment elevation myocardial infarction (STEMI) undergoing primary stenting have produced conflicting results. Methods: Formal searches of electronic databases (Medline, Cochrane) from January 1990 to April 2009 were performed. Five trials randomizing 2,937 patients (1,475 in the abciximab group, 1,462 in the placebo group) were included in the analysis. Results: When compared with placebo, abciximab was not associated with a significant reduction in the odds of 30‐day (OR 0.71, 95% CI: 0.45–1.14, P = 0.16) or long‐term (OR 0.85, 95% CI: 0.48–1.50, P = 0.57) mortality. Similarly, the rate of reinfarction was not statistically different at 30 days (OR 0.59, 95% CI: 0.30–1.17, P = 0.13) or at long‐term follow‐up (OR 0.67; 95% CI: 0.39–1.16, P = 0.16). However, when trials with upstream use of thienopyridines were excluded, abciximab was associated with a significant reduction in the composite of death or reinfarction at 30 days (OR 0.45; 95% CI: 0.26–0.77, P = 0.004) but not at long‐term follow‐up (OR 0.59; 95% CI: 0.27–1.28, P = 0.18). Conclusion: Routine use of abciximab in patients with STEMI treated with primary stenting may reduce short‐term rates of death or reinfarction in patients not administered preprocedural thienopyridine therapy, but does not appear to be beneficial in those who receive preprocedural thienopyridines. © 2009 Wiley‐Liss, Inc. 相似文献
4.
5.
Yosuke Kawamura Hiroaki Yokoyama Kazutaka Kitayama Naotake Miura Misato Hamadate Daiki Nagawa Masashi Nozaka Masamichi Nakata Fumie Nishizaki Kenji Hanada Takashi Yokota Masahiro Yamada Takumi Higuma Hirofumi Tomita 《Clinical cardiology》2021,44(1):91-99
Complete atrioventricular block (CAVB) is a common complication of ST‐segment elevation myocardial infarction (STEMI). Although STEMI patients complicated with CAVB had a higher mortality in the thrombolytic era, little is known about the impact of CAVB on STEMI patients who underwent primary percutaneous coronary intervention (PCI). The study aimed at evaluating the clinical impact of CAVB on STEMI patients in the primary PCI era. We consecutively enrolled 1295 STEMI patients undergoing primary PCI within 24 hours from onset. Patients were divided into two groups according to the infarct location: anterior STEMI (n = 640) and nonanterior STEMI (n = 655). The outcomes were all‐cause death and major adverse cardiocerebrovascular events (MACCE) with a median follow‐up period of 3.8 (1.7–6.6) years. Eighty‐one patients (6.3%) developed CAVB. The incidence of CAVB was lower in anterior STEMI patients than in nonanterior STEMI (1.7% vs 10.7%, p < .05). Anterior STEMI patients with CAVB had a higher incidence of all‐cause deaths (82% vs 20%, p < .05) and MACCE (82% vs 25%, p < .05) than those without CAVB. Although higher incidence of all‐cause deaths was found more in nonanterior STEMI patients with CAVB compared with those without CAVB (30% vs 18%, p < .05), there was no significant difference in the incidence of MACCE (24% vs 19%). Multivariate analysis showed that CAVB was an independent predictor for all‐cause mortality and MACCE in anterior STEMI patients, but not in nonanterior STEMI. CAVB is rare in anterior STEMI patients, but remains a poor prognostic complication even in the primary PCI era. 相似文献
6.
L. Hee X. Brennan J. Chen C. Allman G. A. Whalley J. K. French C. P. Juergens L. Thomas 《Internal medicine journal》2014,44(3):291-294
This study evaluated the effect of restrictive filling pattern (RFP) on 5‐year outcomes in patients following ST‐segment elevation myocardial infarction (STEMI). A hundred STEMI patients treated either by rescue or primary percutaneous coronary intervention with an echocardiogram performed within 6 weeks of STEMI comprised the study group. Creatinine kinase (CK) and left ventricular ejection fraction were independent determinants of RFP, and RFP was an independent predictor of cardiac and all‐cause mortality at median follow up of 5 years. 相似文献
7.
8.
9.
10.
11.
A randomized study of prourokinase during primary percutaneous coronary intervention in acute ST‐segment elevation myocardial infarction 下载免费PDF全文
Wei Geng Qi Zhang Jingmin Liu Xiang Tian Libo Zhen Da Song Ying Yang Haiyun Meng Yafang Wang Jianjun Chen 《Journal of interventional cardiology》2018,31(2):136-143
Objectives
To evaluate the efficacy and safety of intracoronary administration of prourokinase via balloon catheter during primary percutaneous coronary interventions (PCI) in patients with acute ST‐segment elevation myocardial infarction (STEMI).Methods
Acute STEMI patients underwent primary PCI were randomly divided into two groups: intracoronary prourokinase (IP) group (n = 118) and control group (n = 112). During primary PCI, prourokinase or saline were injected to the distal end of the culprit lesion via balloon catheter after balloon catheter dilatation. Demographic and clinical characteristics, infarct size, myocardial reperfusion, and cardiac functions were evaluated and compared between two groups. Hemorrhagic complications and MACE occurred in the 6‐months follow up were recorded.Results
No significant differences were observed between two groups with respect to baseline demographic, clinical, and angiographic characteristics (P > 0.05). In IP group, more patients had complete ST segment resolution (>70%) compared with control group (P < 0.05). Patients in IP group showed lower levels of serum CK, CK‐MB and TnI, and a much higher myocardial blood flow (MBF) than those in control group (P < 0.05). No significant differences of TIMI major or minor bleeding complications were observed between the two groups (P > 0.05). At 6‐months follow‐up, there was a trend that patients in the IP group had a less chance to have MACE, though it was not statistically different (8.5% vs 12.5%, P > 0.05).Conclusions
Intracoronary administration of prourokinase via balloon catheter during primary PCI effectively improved myocardial perfusion in STEMI patients. 相似文献12.
Joost D.E. Haeck MD Youlan L. Gu MD Mathijs Vogelzang MD PhD Luc Bilodeau MD Mitchell W. Krucoff MD Jan G.P. Tijssen PhD Robbert J. De Winter MD PhD Felix Zijlstra MD PhD Karel T. Koch MD PhD 《Catheterization and cardiovascular interventions》2010,75(5):701-706
Objectives : The aim of the study was to evaluate whether the “Quantitative Blush Evaluator” (QuBE) score is associated with measures of myocardial reperfusion in patients with ST‐segment elevation myocardial infarction (STEMI) treated in two hospitals with 24/7 coronary intervention facilities. Background : QuBE is an open source computer program to quantify myocardial perfusion. Although QuBE has shown to be practical and feasible in the patients enrolled in the Thrombus Aspiration during Percutaneous Coronary Intervention in Acute Myocardial Infarction Study (TAPAS), QuBE has not yet been verified on reperfusion outcomes of primary percutaneous coronary intervention (PCI) patients treated in other catheterization laboratories. Methods : Core lab adjudicated angiographic outcomes and QuBE values were assessed on angiograms of patients who were enrolled in the PRoximal Embolic Protection in Acute myocardial infarction and Resolution of ST‐Elevation (PREPARE) trial. ST‐segment resolution immediately after PCI measured by continuous ST Holter monitoring was calculated by a blinded core lab. Results : The QuBE score could be assessed on 229 of the 284 angiograms (81%) and was significantly associated with visually assessed myocardial blush grade (P < 0.0001). Patients with improved postprocedural Thrombolysis in Myocardial Infarction‐graded flow, myocardial blush grade, ST‐segment resolution immediately after PCI, or a small infarct size measured by peak CK‐MB had a significant better QuBE score. Conclusions : QuBE is feasible and applicable at angiograms of patients with STEMI recorded at other catheterization laboratories and is associated with measures of myocardial reperfusion. © 2010 Wiley‐Liss, Inc. 相似文献
13.
14.
One‐year outcome from an all‐comers population of patients with ST‐segment elevation myocardial infarction treated with biolimus‐eluting stent with biodegradable polymer 下载免费PDF全文
Fabrizio Tomai MD FACC FESC Leonardo De Luca MD PHD FACC Luca Altamura MD Francesco Versaci MD FACC Mauro Pennacchi MD Igino Proietti MD Anna S. Ghini MD PHD Pierfrancesco Corvo MD Giovanni De Persio MD Alessandro Petrolini MD Antonella Tommasino MD Gennaro Sardella MD 《Catheterization and cardiovascular interventions》2015,85(3):352-358
15.
A 12–month angiographic and optical coherence tomography follow‐up after bioresorbable vascular scaffold implantation in patients with ST‐segment elevation myocardial infarction 下载免费PDF全文
Janusz Kochman MD PhD Mariusz Tomaniak MD Łukasz Kołtowski MD PhD Jacek Jąkała MD PhD Klaudia Proniewska MSC PhD Jacek Legutko MD PhD Tomasz Roleder MD PhD Arkadiusz Pietrasik MD PhD Adam Rdzanek MD PhD Wacław Kochman MD PhD Salvatore Brugaletta MD PhD Grzegorz L. Kaluza MD PhD 《Catheterization and cardiovascular interventions》2015,86(4):E180-E189
16.
17.
No long‐term clinical benefit from manual aspiration thrombectomy in ST‐elevation myocardial infarction patients. Data from NRDES registry 下载免费PDF全文
Zbigniew Siudak MD PhD Waldemar Mielecki MD PhD Artur Dziewierz MD PhD Tomasz Rakowski MD PhD Jacek Legutko MD PhD Stanisław Bartuś MD PhD Krzysztof L. Bryniarski MD Łukasz Partyka MD PhD Dariusz Dudek MD PhD 《Catheterization and cardiovascular interventions》2015,85(1):E16-E22
18.
Yanbo Wang Yunfa Jiang Wei Zhi Yang Fu Qing Wang Jianli Zhou Shaochen Zheng Guozhen Hao 《Clinical cardiology》2021,44(1):123-128
BackgroundPrevious studies have confirmed the safety and feasibility of half‐dose ticagrelor in Chinese patients with acute coronary syndrome, but currently there is no plan for the use of ticagrelor for Chinese ST‐segment elevation myocardial infarction (STEMI) patients.HypothesisIt is safe and feasible of low‐dose ticagrelor in patients with STEMI.MethodsThe STEMI patients who were undergoing emergency intervention and taking ticagrelor were enrolled. Patients whose level of platelet aggregation rate (PAR) less than 30% after 7‐day treatment with standard‐dose ticagrelor were randomly divided into low‐dose group (LD group, 45 mg twice daily) and standard‐dose group (SD group, 90 mg twice daily). The changes of levels of platelet parameters were compared between the two groups. The incidence of major adverse cardiac events (MACE), bleeding events were compared between the two groups within 6 months of follow‐up.ResultsThe levels of PAR in the SD group decreased compared with baseline, and was lower than those of LD group at the same time point. The levels of platelet distribution width in both groups decreased from the baseline values (all p < .05) at 1, 3, and 6 months after grouping treatment, but there was no significant difference between the two groups. The incidence of MACE was similar between the two groups of patients. There were decreasing trends in the incidences of minimal bleeding event, minor bleeding event, dyspnea, and gout in the LD group.ConclusionIt is safe and feasible of low‐dose ticagrelor for patients with STEMI based on the monitoring of PAR. 相似文献
19.
20.
The predictive value of global longitudinal strain on clinical outcome in patients with ST‐segment elevation myocardial infarction and preserved systolic function 下载免费PDF全文
Ahmed Bendary MD Wael Tawfeek MD Mohammed Mahros MD Mohamed Salem MD PhD 《Echocardiography (Mount Kisco, N.Y.)》2018,35(7):915-921